{"id":724827,"date":"2023-01-20T16:33:33","date_gmt":"2023-01-20T21:33:33","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/anpac-bio-medical-sciences-announces-receipt-of-staff-delisting-determination-from-nasdaq-intends-to-request-a-hearing\/"},"modified":"2023-01-20T16:33:33","modified_gmt":"2023-01-20T21:33:33","slug":"anpac-bio-medical-sciences-announces-receipt-of-staff-delisting-determination-from-nasdaq-intends-to-request-a-hearing","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/anpac-bio-medical-sciences-announces-receipt-of-staff-delisting-determination-from-nasdaq-intends-to-request-a-hearing\/","title":{"rendered":"AnPac Bio-Medical Sciences Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request A Hearing"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">New York, NY, Jan.  20, 2023  (GLOBE NEWSWIRE) &#8212; AnPac Bio-Medical Science Co.,\u00a0Ltd. (the \u201cCompany\u201d) (Nasdaq: <u>ANPC<\/u>), a biotechnology company with operations in the United States and China focused on early cancer screening and detection announced that, on\u00a0January 13, 2023, it received a Staff determination letter (the \u201cLetter\u201d) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (\u201cNasdaq\u201d) notifying the Company of the Staff\u2019s determination to delist the Company\u2019s securities from The Nasdaq Capital Market due to the Company\u2019s failure to comply with the minimum $2.5 million stockholders\u2019 equity requirement for continued listing on The Nasdaq Capital Market (the \u201cEquity Rule\u201d), unless the Company timely requests a hearing before a Nasdaq Hearings Panel (the \u201cPanel\u201d). Accordingly, the Company intends to timely request a hearing. The hearing request will automatically stay any delisting or suspension action relating to the Company\u2019s American Depositary Shares through the hearing and the expiration of any additional extension period granted by the Panel following the hearing.<\/p>\n<p align=\"justify\">At the hearing, the Company intends to present a plan to achieve and sustain compliance with the Equity Rule and all applicable requirements for continued listing and to request an extension of time within which to complete its compliance plan. However, there can be no assurance that the Panel will grant the Company\u2019s request for a further extension or that the Company will ultimately regain compliance with all applicable requirements for continued listing.<\/p>\n<p align=\"justify\">\n        <strong>About <\/strong><br \/>\n        <strong>AnPac<\/strong><br \/>\n        <strong> Bio<\/strong>&#8211;<strong>Medical Science Co., Ltd.<\/strong><\/p>\n<p align=\"justify\">AnPac Bio-Medical Science Co., Ltd.is a biotechnology company focused on early cancer screening and detection, with 155 issued patents as of June 30, 2022. With two certified clinical laboratories in China and one CLIA and CAP accredited clinical laboratory in the United States, AnPac Bio performs a suite of cancer screening and detection tests, including CDA (Cancer Differentiation Analysis), bio-chemical, immunological, and genomics tests.<\/p>\n<p align=\"justify\">For more information, please visit:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=oeLCS9ag0ZdULDIueLOpUcr3Qyx8knhgegMKjjroKMz2eHgFs3YojJbTZwYVpOnO3qqqHotOSw54PVlUF0c2ogw-QSuQ5XP2HBRoWMxf6Ds=\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/www.Anpacbio.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>For investor and media inquiries, please contact:<\/strong>\n      <\/p>\n<p>Ascent Investor Relations LLC<br \/>Ms. Tina Xiao<br \/>Phone: +1-917-609-0333 (U.S.)<br \/>Email: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=C33Pp2K2NHrf6EBb42jiG0KVBuCGAlfwxqijHy_smnDa4NhHkM9FHo19DLSOcDLtwXSrOizi1uNvb-W7grclGw==\" rel=\"nofollow noopener\" target=\"_blank\">T<\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Xqzbi9wY4yoFrNDYAl0gWqDaWZkN88vH68eLo-79edHc1jHzhYckzhBjeNtMsMaVBPMpq6m6mWw3YPd9JonTpyBCLzAILsP19QrfivUtYNY=\" rel=\"nofollow noopener\" target=\"_blank\">ina.xiao@ascent-ir.com<\/a><\/p>\n<p align=\"justify\">\n        <strong>Safe Harbor Statement<\/strong>\n      <\/p>\n<p align=\"justify\">This announcement contains forward-looking statements within the meaning of Section\u00a027A of the Securities Act of 1933 and Section\u00a021E of the Securities Exchange Act of 1934. These forward-looking statements are made under the \u201csafe harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995 and are relating to the Company\u2019s future financial and operating performance. The Company has attempted to identify forward-looking statements by terminologies including \u201cbelieves,\u201d \u201cestimates,\u201d \u201canticipates,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201cprojects,\u201d \u201cintends,\u201d \u201cpotential,\u201d \u201ctarget,\u201d \u201caim,\u201d \u201cpredict,\u201d \u201coutlook,\u201d \u201cseek,\u201d \u201cgoal\u201d \u201cobjective,\u201d \u201cassume,\u201d \u201ccontemplate,\u201d \u201ccontinue,\u201d \u201cpositioned,\u201d \u201cforecast,\u201d \u201clikely,\u201d \u201cmay,\u201d \u201ccould,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201capproximately\u201d or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company\u2019s control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company\u2019s actual results to be materially different from those expressed or implied by any forward-looking statement. Known and unknown risks, uncertainties and other factors include, but are not limited to, our ability to comply with Nasdaq Listing Rules, the implementation of our business model and growth strategies; trends and competition in the cancer screening and detection market; our expectations regarding demand for and market acceptance of our cancer screening and detection tests and our ability to expand our customer base; our ability to obtain and maintain intellectual property protections for our CDA technology and our continued research and development to keep pace with technology developments; our ability to obtain and maintain regulatory approvals from the NMPA, the FDA and the relevant U.S. states and have our laboratories certified or accredited by authorities including the CLIA; our future business development, financial condition and results of operations and our ability to obtain financing cost-effectively; potential changes of government regulations; general economic and business conditions in China and elsewhere; our ability to hire and maintain key personnel; our relationship with our major business partners and customers; and the duration of the coronavirus outbreaks and their potential adverse impact on the economic conditions and financial markets and our business and financial performance, such as resulting from reduced commercial activities due to quarantines and travel restrictions instituted by China, the U.S. and many other countries around the world to contain the spread of the virus. Additionally, all forward-looking statements are subject to the \u201cRisk Factors\u201d detailed from time to time in the Company\u2019s most recent Annual Report on Form\u00a020-F and other filings with the U.S. Securities and Exchange Commission. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.<\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczMjk2MCM1MzY0NTcxIzUwMDExMjIyOQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NTQ4MGUyZjUtMTk1MS00MTYyLWJiOGEtMjM4ODFjODUxZjRkLTUwMDExMjIyOQ==\/tiny\/ANPAC-BIO-MEDICAL-SCIENCE-CO-L.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>New York, NY, Jan. 20, 2023 (GLOBE NEWSWIRE) &#8212; AnPac Bio-Medical Science Co.,\u00a0Ltd. (the \u201cCompany\u201d) (Nasdaq: ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection announced that, on\u00a0January 13, 2023, it received a Staff determination letter (the \u201cLetter\u201d) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (\u201cNasdaq\u201d) notifying the Company of the Staff\u2019s determination to delist the Company\u2019s securities from The Nasdaq Capital Market due to the Company\u2019s failure to comply with the minimum $2.5 million stockholders\u2019 equity requirement for continued listing on The Nasdaq Capital Market (the \u201cEquity Rule\u201d), unless the Company timely requests a hearing before a Nasdaq Hearings Panel (the \u201cPanel\u201d). Accordingly, the Company &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/anpac-bio-medical-sciences-announces-receipt-of-staff-delisting-determination-from-nasdaq-intends-to-request-a-hearing\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;AnPac Bio-Medical Sciences Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request A Hearing&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-724827","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AnPac Bio-Medical Sciences Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request A Hearing - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/anpac-bio-medical-sciences-announces-receipt-of-staff-delisting-determination-from-nasdaq-intends-to-request-a-hearing\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AnPac Bio-Medical Sciences Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request A Hearing - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"New York, NY, Jan. 20, 2023 (GLOBE NEWSWIRE) &#8212; AnPac Bio-Medical Science Co.,\u00a0Ltd. (the \u201cCompany\u201d) (Nasdaq: ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection announced that, on\u00a0January 13, 2023, it received a Staff determination letter (the \u201cLetter\u201d) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (\u201cNasdaq\u201d) notifying the Company of the Staff\u2019s determination to delist the Company\u2019s securities from The Nasdaq Capital Market due to the Company\u2019s failure to comply with the minimum $2.5 million stockholders\u2019 equity requirement for continued listing on The Nasdaq Capital Market (the \u201cEquity Rule\u201d), unless the Company timely requests a hearing before a Nasdaq Hearings Panel (the \u201cPanel\u201d). Accordingly, the Company &hellip; Continue reading &quot;AnPac Bio-Medical Sciences Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request A Hearing&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/anpac-bio-medical-sciences-announces-receipt-of-staff-delisting-determination-from-nasdaq-intends-to-request-a-hearing\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-20T21:33:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczMjk2MCM1MzY0NTcxIzUwMDExMjIyOQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anpac-bio-medical-sciences-announces-receipt-of-staff-delisting-determination-from-nasdaq-intends-to-request-a-hearing\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anpac-bio-medical-sciences-announces-receipt-of-staff-delisting-determination-from-nasdaq-intends-to-request-a-hearing\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AnPac Bio-Medical Sciences Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request A Hearing\",\"datePublished\":\"2023-01-20T21:33:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anpac-bio-medical-sciences-announces-receipt-of-staff-delisting-determination-from-nasdaq-intends-to-request-a-hearing\\\/\"},\"wordCount\":865,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anpac-bio-medical-sciences-announces-receipt-of-staff-delisting-determination-from-nasdaq-intends-to-request-a-hearing\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczMjk2MCM1MzY0NTcxIzUwMDExMjIyOQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anpac-bio-medical-sciences-announces-receipt-of-staff-delisting-determination-from-nasdaq-intends-to-request-a-hearing\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anpac-bio-medical-sciences-announces-receipt-of-staff-delisting-determination-from-nasdaq-intends-to-request-a-hearing\\\/\",\"name\":\"AnPac Bio-Medical Sciences Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request A Hearing - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anpac-bio-medical-sciences-announces-receipt-of-staff-delisting-determination-from-nasdaq-intends-to-request-a-hearing\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anpac-bio-medical-sciences-announces-receipt-of-staff-delisting-determination-from-nasdaq-intends-to-request-a-hearing\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczMjk2MCM1MzY0NTcxIzUwMDExMjIyOQ==\",\"datePublished\":\"2023-01-20T21:33:33+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anpac-bio-medical-sciences-announces-receipt-of-staff-delisting-determination-from-nasdaq-intends-to-request-a-hearing\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anpac-bio-medical-sciences-announces-receipt-of-staff-delisting-determination-from-nasdaq-intends-to-request-a-hearing\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anpac-bio-medical-sciences-announces-receipt-of-staff-delisting-determination-from-nasdaq-intends-to-request-a-hearing\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczMjk2MCM1MzY0NTcxIzUwMDExMjIyOQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczMjk2MCM1MzY0NTcxIzUwMDExMjIyOQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anpac-bio-medical-sciences-announces-receipt-of-staff-delisting-determination-from-nasdaq-intends-to-request-a-hearing\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AnPac Bio-Medical Sciences Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request A Hearing\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AnPac Bio-Medical Sciences Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request A Hearing - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/anpac-bio-medical-sciences-announces-receipt-of-staff-delisting-determination-from-nasdaq-intends-to-request-a-hearing\/","og_locale":"en_US","og_type":"article","og_title":"AnPac Bio-Medical Sciences Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request A Hearing - Market Newsdesk","og_description":"New York, NY, Jan. 20, 2023 (GLOBE NEWSWIRE) &#8212; AnPac Bio-Medical Science Co.,\u00a0Ltd. (the \u201cCompany\u201d) (Nasdaq: ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection announced that, on\u00a0January 13, 2023, it received a Staff determination letter (the \u201cLetter\u201d) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (\u201cNasdaq\u201d) notifying the Company of the Staff\u2019s determination to delist the Company\u2019s securities from The Nasdaq Capital Market due to the Company\u2019s failure to comply with the minimum $2.5 million stockholders\u2019 equity requirement for continued listing on The Nasdaq Capital Market (the \u201cEquity Rule\u201d), unless the Company timely requests a hearing before a Nasdaq Hearings Panel (the \u201cPanel\u201d). Accordingly, the Company &hellip; Continue reading \"AnPac Bio-Medical Sciences Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request A Hearing\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/anpac-bio-medical-sciences-announces-receipt-of-staff-delisting-determination-from-nasdaq-intends-to-request-a-hearing\/","og_site_name":"Market Newsdesk","article_published_time":"2023-01-20T21:33:33+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczMjk2MCM1MzY0NTcxIzUwMDExMjIyOQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anpac-bio-medical-sciences-announces-receipt-of-staff-delisting-determination-from-nasdaq-intends-to-request-a-hearing\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anpac-bio-medical-sciences-announces-receipt-of-staff-delisting-determination-from-nasdaq-intends-to-request-a-hearing\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AnPac Bio-Medical Sciences Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request A Hearing","datePublished":"2023-01-20T21:33:33+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anpac-bio-medical-sciences-announces-receipt-of-staff-delisting-determination-from-nasdaq-intends-to-request-a-hearing\/"},"wordCount":865,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anpac-bio-medical-sciences-announces-receipt-of-staff-delisting-determination-from-nasdaq-intends-to-request-a-hearing\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczMjk2MCM1MzY0NTcxIzUwMDExMjIyOQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anpac-bio-medical-sciences-announces-receipt-of-staff-delisting-determination-from-nasdaq-intends-to-request-a-hearing\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/anpac-bio-medical-sciences-announces-receipt-of-staff-delisting-determination-from-nasdaq-intends-to-request-a-hearing\/","name":"AnPac Bio-Medical Sciences Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request A Hearing - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anpac-bio-medical-sciences-announces-receipt-of-staff-delisting-determination-from-nasdaq-intends-to-request-a-hearing\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anpac-bio-medical-sciences-announces-receipt-of-staff-delisting-determination-from-nasdaq-intends-to-request-a-hearing\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczMjk2MCM1MzY0NTcxIzUwMDExMjIyOQ==","datePublished":"2023-01-20T21:33:33+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anpac-bio-medical-sciences-announces-receipt-of-staff-delisting-determination-from-nasdaq-intends-to-request-a-hearing\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/anpac-bio-medical-sciences-announces-receipt-of-staff-delisting-determination-from-nasdaq-intends-to-request-a-hearing\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anpac-bio-medical-sciences-announces-receipt-of-staff-delisting-determination-from-nasdaq-intends-to-request-a-hearing\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczMjk2MCM1MzY0NTcxIzUwMDExMjIyOQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczMjk2MCM1MzY0NTcxIzUwMDExMjIyOQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anpac-bio-medical-sciences-announces-receipt-of-staff-delisting-determination-from-nasdaq-intends-to-request-a-hearing\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AnPac Bio-Medical Sciences Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request A Hearing"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/724827","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=724827"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/724827\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=724827"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=724827"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=724827"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}